163 related articles for article (PubMed ID: 7562586)
1. In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides.
Crooke RM; Graham MJ; Cooke ME; Crooke ST
J Pharmacol Exp Ther; 1995 Oct; 275(1):462-73. PubMed ID: 7562586
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic properties of several novel oligonucleotide analogs in mice.
Crooke ST; Graham MJ; Zuckerman JE; Brooks D; Conklin BS; Cummins LL; Greig MJ; Guinosso CJ; Kornbrust D; Manoharan M; Sasmor HM; Schleich T; Tivel KL; Griffey RH
J Pharmacol Exp Ther; 1996 May; 277(2):923-37. PubMed ID: 8627575
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice.
Saijo Y; Perlaky L; Wang H; Busch H
Oncol Res; 1994; 6(6):243-9. PubMed ID: 7865900
[TBL] [Abstract][Full Text] [Related]
4. Antiviral activity and ocular kinetics of antisense oligonucleotides designed to inhibit CMV replication.
Henry SP; Miner RC; Drew WL; Fitchett J; York-Defalco C; Rapp LM; Levin AA
Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2646-51. PubMed ID: 11581212
[TBL] [Abstract][Full Text] [Related]
5. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides.
Bennett CF; Chiang MY; Chan H; Shoemaker JE; Mirabelli CK
Mol Pharmacol; 1992 Jun; 41(6):1023-33. PubMed ID: 1352033
[TBL] [Abstract][Full Text] [Related]
6. In vitro toxicology and pharmacokinetics of antisense oligonucleotides.
Crooke RM
Anticancer Drug Des; 1991 Dec; 6(6):609-46. PubMed ID: 1772572
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of a 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats.
Cossum PA; Truong L; Owens SR; Markham PM; Shea JP; Crooke ST
J Pharmacol Exp Ther; 1994 Apr; 269(1):89-94. PubMed ID: 8169856
[TBL] [Abstract][Full Text] [Related]
8. Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats.
Geary RS; Khatsenko O; Bunker K; Crooke R; Moore M; Burckin T; Truong L; Sasmor H; Levin AA
J Pharmacol Exp Ther; 2001 Mar; 296(3):898-904. PubMed ID: 11181922
[TBL] [Abstract][Full Text] [Related]
9. Spinal distribution and metabolism of 2'-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats.
Butler M; Hayes CS; Chappell A; Murray SF; Yaksh TL; Hua XY
Neuroscience; 2005; 131(3):705-15. PubMed ID: 15730875
[TBL] [Abstract][Full Text] [Related]
10. Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate.
Sands H; Gorey-Feret LJ; Cocuzza AJ; Hobbs FW; Chidester D; Trainor GL
Mol Pharmacol; 1994 May; 45(5):932-43. PubMed ID: 8190109
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of antisense oligonucleotides in rat liver homogenates.
Crooke RM; Graham MJ; Martin MJ; Lemonidis KM; Wyrzykiewiecz T; Cummins LL
J Pharmacol Exp Ther; 2000 Jan; 292(1):140-9. PubMed ID: 10604941
[TBL] [Abstract][Full Text] [Related]
12. Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats.
Cossum PA; Sasmor H; Dellinger D; Truong L; Cummins L; Owens SR; Markham PM; Shea JP; Crooke S
J Pharmacol Exp Ther; 1993 Dec; 267(3):1181-90. PubMed ID: 8166890
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbit.
Leeds JM; Henry SP; Truong L; Zutshi A; Levin AA; Kornbrust D
Drug Metab Dispos; 1997 Aug; 25(8):921-6. PubMed ID: 9280399
[TBL] [Abstract][Full Text] [Related]
14. Effect of antisense oligonucleotides on cytokine release from human keratinocytes in an in vitro model of skin.
Crooke RM; Crooke ST; Graham MJ; Cooke ME
Toxicol Appl Pharmacol; 1996 Sep; 140(1):85-93. PubMed ID: 8806873
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of human cytomegalovirus replication in a human retinal epithelial cell model by antisense oligonucleotides.
Detrick B; Nagineni CN; Grillone LR; Anderson KP; Henry SP; Hooks JJ
Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):163-9. PubMed ID: 11133862
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.
Geary RS; Leeds JM; Fitchett J; Burckin T; Truong L; Spainhour C; Creek M; Levin AA
Drug Metab Dispos; 1997 Nov; 25(11):1272-81. PubMed ID: 9351904
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution of 68Ga-labelled phosphodiester, phosphorothioate, and 2'-O-methyl phosphodiester oligonucleotides in normal rats.
Lendvai G; Velikyan I; Bergström M; Estrada S; Laryea D; Välilä M; Salomäki S; Långström B; Roivainen A
Eur J Pharm Sci; 2005 Sep; 26(1):26-38. PubMed ID: 15941654
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects.
Zhang R; Yan J; Shahinian HK; Amin G; Lu Z; Liu T; Saag MS; Jiang Z; Temsamani J; Martin RR
Clin Pharmacol Ther; 1995 Jul; 58(1):44-53. PubMed ID: 7628182
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of antisense oligonucleotides.
Agrawal S; Temsamani J; Galbraith W; Tang J
Clin Pharmacokinet; 1995 Jan; 28(1):7-16. PubMed ID: 7712663
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats.
Geary RS; Watanabe TA; Truong L; Freier S; Lesnik EA; Sioufi NB; Sasmor H; Manoharan M; Levin AA
J Pharmacol Exp Ther; 2001 Mar; 296(3):890-7. PubMed ID: 11181921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
